Ya Hua Selected Research

Mitogen-Activated Protein Kinases

1/2013	Geldanamycin treatment during cerebral ischemia/reperfusion attenuates p44/42 mitogen-activated protein kinase activation and tissue damage.
9/2012	Role of protease-activated receptor-1 in brain injury after experimental global cerebral ischemia.
9/2009	Thrombin up-regulates vascular endothelial growth factor in experimental gliomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ya Hua Research Topics

Disease

82	Cerebral Hemorrhage 11/2023 - 01/2002
71	Brain Injuries (Brain Injury) 11/2023 - 01/2002
50	Brain Edema (Cerebral Edema) 01/2023 - 02/2002
27	Hematoma 01/2023 - 01/2002
23	Hydrocephalus (Hydrocephaly) 04/2024 - 01/2011
18	Hemorrhage 11/2023 - 09/2005
13	Atrophy 02/2022 - 02/2006
12	Brain Ischemia (Cerebral Ischemia) 01/2019 - 04/2002
11	Edema (Dropsy) 10/2022 - 02/2002
11	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 01/2021 - 11/2010
9	Iron Overload 11/2023 - 12/2003
9	Stroke (Strokes) 01/2021 - 02/2004
9	Infarction (Infarctions) 02/2018 - 04/2002
8	Neuroinflammatory Diseases 04/2021 - 09/2015
5	Ischemic Stroke 01/2021 - 02/2009
4	Inflammation (Inflammations) 01/2023 - 09/2015
4	Hemorrhagic Stroke 01/2022 - 10/2016
4	Hypoxia (Hypoxemia) 01/2016 - 06/2002
4	Glioma (Gliomas) 01/2016 - 01/2008
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 07/2012 - 04/2005
3	Thrombosis (Thrombus) 01/2022 - 12/2002
3	Ischemia 11/2019 - 09/2009
3	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2016 - 01/2013
3	Parkinson Disease (Parkinson's Disease) 11/2007 - 01/2005
2	Nervous System Diseases (Neurological Disorders) 01/2021 - 01/2002
2	Hemolysis 01/2020 - 01/2017
2	Neoplasms (Cancer) 01/2016 - 01/2008
2	Neurologic Manifestations (Neurological Manifestations) 09/2015 - 02/2004
2	Intracranial Hemorrhages (Intracranial Hemorrhage) 10/2014 - 08/2014
2	Hyperglycemia 09/2009 - 04/2007
1	Cognitive Dysfunction 02/2022
1	Intracranial Thrombosis (Cerebral Thrombosis) 01/2021
1	Weight Loss (Weight Reduction) 01/2021

Drug/Important Bio-Agent (IBA)

53	IronIBA 04/2024 - 02/2002
36	Thrombin FDA Link 08/2021 - 01/2002
24	Deferoxamine (Desferal)FDA LinkGeneric 01/2023 - 02/2002
22	Hemoglobins (Hemoglobin)IBA 10/2022 - 02/2002
16	Proteins (Proteins, Gene)FDA Link 11/2022 - 01/2002
10	Minocycline (Cyclops)FDA LinkGeneric 11/2023 - 03/2009
10	Lipocalin-2IBA 01/2022 - 04/2013
8	Liposomes (Liposome)IBA 04/2024 - 02/2016
8	Clodronic Acid (Clodronate)IBA 04/2024 - 02/2016
7	Ferritins (Ferritin)IBA 01/2021 - 12/2003
7	Peptide Hydrolases (Proteases)FDA Link 12/2016 - 10/2006
6	Heme Oxygenase-1IBA 10/2021 - 12/2003
6	PeroxiredoxinsIBA 01/2021 - 01/2020
6	salicylhydroxamic acid (SHAM)IBA 01/2016 - 04/2005
5	Chelating AgentsIBA 01/2019 - 02/2002
5	Tissue Plasminogen Activator (Alteplase)FDA Link 09/2009 - 01/2002
4	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 11/2023 - 01/2016
4	Estrogens (Estrogen)FDA Link 01/2022 - 07/2005
4	Complement System Proteins (Complement)IBA 01/2021 - 07/2005
4	Thrombin Receptors (Thrombin Receptor)IBA 01/2016 - 04/2002
3	Glucose (Dextrose)FDA LinkGeneric 02/2018 - 04/2007
3	Oxygen (Dioxygen)IBA 02/2018 - 04/2007
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014 - 03/2006
3	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2013 - 11/2004
3	Mitogen-Activated Protein KinasesIBA 01/2013 - 09/2009
3	Messenger RNA (mRNA)IBA 01/2013 - 01/2002
3	argatroban (MPQA)FDA Link 01/2008 - 12/2002
3	Oxidopamine (6 Hydroxydopamine)IBA 11/2007 - 01/2005
3	Transferrin (beta 2 Transferrin)IBA 02/2005 - 12/2003
2	Aurintricarboxylic AcidIBA 11/2023 - 01/2019
2	Eosine Yellowish-(YS) (Eosin)IBA 01/2022 - 01/2011
2	Hematoxylin (Haematoxylon)IBA 01/2022 - 01/2011
2	Complement C3 (C3 Complement)IBA 01/2021 - 12/2006
2	AlbuminsIBA 01/2021 - 01/2013
2	Hemin (Panhematin)FDA Link 01/2019 - 01/2011
2	CytokinesIBA 12/2016 - 03/2009
2	Estrogen ReceptorsIBA 01/2016 - 07/2005
2	Fulvestrant (Faslodex)FDA Link 01/2016 - 07/2005
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016 - 09/2009
2	EnzymesIBA 01/2016 - 01/2016
2	Heme (Haem)IBA 01/2016 - 12/2006
2	ImmunosorbentsIBA 01/2016 - 01/2016
2	Tamoxifen FDA LinkGeneric 01/2016 - 01/2011
2	Collagenases (Collagenase)FDA Link 06/2011 - 12/2002
2	Protein Glutamine gamma Glutamyltransferase 2IBA 01/2011 - 01/2009
2	2- (2- amino- 3- methoxyphenyl)- 4H- 1- benzopyran- 4- oneIBA 09/2009 - 05/2007
2	Complement C5 (Complement 5)IBA 12/2006 - 05/2004
2	HirudinsIBA 02/2004 - 01/2002
2	Transferrin Receptors (Transferrin Receptor)IBA 12/2003 - 12/2003
1	enhanced green fluorescent proteinIBA 11/2022
1	NeurotoxinsIBA 10/2022
1	Fibrinogen (Factor I)FDA Link 01/2022
1	Laminin (Merosin)IBA 01/2022
1	Myelin Basic ProteinIBA 10/2021
1	Proteinase-Activated ReceptorsIBA 01/2021
1	Prothrombin (Factor II)IBA 01/2021
1	conoidin AIBA 01/2020
1	Immunoglobulin G (IgG)IBA 01/2020
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 10/2019
1	Ceruloplasmin (Ferroxidase)IBA 01/2019
1	Complement Inactivating AgentsIBA 01/2019
1	N-acetylheparinIBA 01/2019
1	HemopexinIBA 01/2019
1	Tight Junction ProteinsIBA 01/2018

Therapy/Procedure

14	Therapeutics 01/2023 - 12/2002
8	Intraventricular Injections 11/2023 - 03/2014
2	Injections 08/2021 - 01/2021